Therapeutic Asset Ratings
6,369 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nivolumab
Stage IV Bladder Cancer AJCC v8
M.D. Anderson Cancer Center
P2
B
(63)
Obinutuzumab
Indolent B-Cell Non-Hodgkin Lymphoma
Reid Merryman, MD
P2
B
(63)
Obinutuzumab
Lymphoplasmacytic Lymphoma
Emory University
P2
B
(63)
Pembrolizumab
Advanced Solid Tumours
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
P2
B
(63)
Pembrolizumab
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma
Seda S. Tolu
P2
B
(63)
Pembrolizumab
Fallopian Tube Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Gallbladder Cancer
Merck Sharp & Dohme LLC
P2
B
(63)
Pembrolizumab
Gallbladder Neoplasms
GV20 Therapeutics
P2
B
(63)
Pembrolizumab
Hormone-Resistant Prostate Carcinoma
University of Wisconsin, Madison
P2
B
(63)
Pembrolizumab
Marginal Zone Lymphoma
University of Ulm
P2
B
(63)
Pembrolizumab
Microsatellite Instability
Fate Therapeutics
P2
B
(63)
Pembrolizumab
Microsatellite Stable
NextCure, Inc.
P2
B
(63)
Pembrolizumab
Myxoid Liposarcoma
Valo Therapeutics Oy
P2
B
(63)
Pembrolizumab
Ovarian Clear Cell Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Pancreatic Adenocarcinoma
Mayo Clinic
P2
B
(63)
Pembrolizumab
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
B
(63)
Pembrolizumab
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Mayo Clinic
P2
B
(63)
Pembrolizumab
High Grade B-Cell Lymphoma
Mayo Clinic
P2
B
(63)
Pembrolizumab
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma
City of Hope Medical Center
P2
B
(63)
Pembrolizumab
Sarcoma
Essen Biotech
P2
B
(63)
Pembrolizumab
Synovial Sarcoma
Valo Therapeutics Oy
P2
B
(63)
Retifanlimab
Renal Cell Carcinoma
University of California, San Diego
P2
B
(63)
ROSOPATAMAB
Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited
P2
B
(63)
Toripalimab
Cancer
Nanjing Immunophage Biotech Co., Ltd
P2
B
(63)
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Diffuse Large B-Cell Lymphoma With Chronic Inflammation
Mayo Clinic
P2/3
B
(63)
Showing 651 to 675 of 6,369 assets
Previous
Page 27 of 255
Next